Panagora Asset Management’s Keros Therapeutics KROS Stock Holding History

Panagora Asset Management’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$599K	Buy	55,985 +21,329	+62%	+$238K	﹤0.01%	851
2026 Q1	$383K	Sell	34,656 -88,165	-72%	-$1.36M	﹤0.01%	913
2025 Q4	$2.5M	Buy	122,821 +92,360	+303%	+$1.62M	0.01%	514
2025 Q3	$482K	Buy	+30,461	New	+$450K	﹤0.01%	812
2021 Q1	–	Sell	-14	Closed	-$1K	–	2871
2020 Q4	$1K	Buy	+14	New	+$882	﹤0.01%	2722

Other funds holding KROS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Panagora Asset Management's KROS Position: Q2 2026 in Review

Panagora Asset Management increased its Keros Therapeutics (KROS) stake by 62% in Q2 2026, buying an estimated $238K and bringing the position to 55,985 shares worth $599K. The position accounts for ﹤0.01% of the portfolio, ranked #851.

Panagora Asset Management first reported a position in KROS in Q4 2020 and has held it in 5 quarters since. The position peaked at $2.5M in Q4 2025. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

Panagora Asset Management held 55,985 shares of Keros Therapeutics worth $599K as of Q2 2026.
Panagora Asset Management bought 21,329 Keros Therapeutics shares in Q2 2026, an estimated $238K.
Keros Therapeutics made up ﹤0.01% of Panagora Asset Management's portfolio in Q2 2026, its #851 holding.
Panagora Asset Management first reported a position in Keros Therapeutics in Q4 2020 and has held it in 5 quarters since.
Panagora Asset Management's Keros Therapeutics position peaked at $2.5M in Q4 2025.
132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Panagora Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.